Marwan G. Fakih, MD, is a professor in the Department of Medical Oncology & Therapeutics Research, associate director of Clinical Sciences, medical director of Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program at City of Hope.
CheckMate 8HW Expanded Analysis at ASCO 2025: Implications for Treatment Decisions in MSI-H mCRC
June 23rd 2025Panelists discuss how doublet immunotherapy with ipilimumab and nivolumab provides superior outcomes compared to single-agent PD-1 therapy or chemotherapy in microsatellite instability-high colorectal cancer, supporting the “hit hard, hit early” approach.
Read More
Expert Insights: BREAKWATER Survival Data Update From ASCO 2025
June 23rd 2025Panelists discuss how the BREAKWATER trial demonstrates that upfront treatment with encorafenib plus cetuximab significantly improves outcomes in BRAF V600E-mutated colorectal cancer, turning a historically poor prognostic marker into a targetable opportunity.
Read More
DPD Testing and Medication Dosage Adjustments in mCRC Patients
June 16th 2025Panelists discuss how dihydropyrimidine dehydrogenase testing remains controversial with institutions debating whether to implement universal pharmacogenomic testing given the challenges of standardization, genotype-phenotype correlation, and low incidence of severe deficiency.
Read More
The Importance of Biomarker Testing in mCRC
June 16th 2025John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS; and Katrina S. Pedersen, MD, discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for microsatellite instability-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.
Read More
FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD
March 3rd 2025Marwan G. Fakih, MD discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial, and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.
Read More
Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Read More
Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Read More
Considerations for Platinum-based Therapy
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
Read More
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Read More
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Read More
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
Read More
Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Read More
Overview of Current mCRC Treatment Landscape
Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
Read More